CAJ | 학술논문

目的:评价金龙胶囊对原发性肝癌患者介入治疗后生存质量的影响.方法:选取符合入选标准的病例60例,随机分成两组,治疗组(金龙胶囊联合TACE)30例,对照组(单纯TACE)30例.每30天为1个周期,均完成至少2个周期.观察两组临床症状、AFP变化、肝功能分级改善、不良反应等,用肝癌患者特异性生命质量评价量表,进行生存质量评价.结果:①治疗组CR 0例,PR 7例,SD 18例,PD 5例,控制率(CR+ PR+SD)83.33%;对照组 CR 0例,PR 5例,SD 13例,PD 12例,控制率(CR+ PR+SD)60.00%,治疗组优于对照组(P<0.05).②治疗组患者治疗后检测AFP含量,改善率23.33%、稳定率为60.00%、恶化率为16.67%,对照组患者治疗后血清AFP含量改善率20.00%、稳定率为53.33%、恶化率为26.67%,两组间比较差异无统计学意义(P>0.05).③治疗组肝功能分级(Child-Pugh)改善率、分级控制率优于对照组(P<0.05).④治疗组胃肠反应、白细胞下降、血红蛋白、血小板下降发生率低于对照组,但差异无统计学意义(P>0.05).⑤生存质量的评价:在改善躯体功能、心理功能、社会功能、总生存质量方面,治疗组优于对照组(P<0.05).结论:金龙胶囊配合肝动脉介入化疗可提高临床疗效、改善肝功能、减轻肝癌TACE不良反应、提高患者生存质量,值得临床推广应用.
목적:평개금룡효낭대원발성간암환자개입치료후생존질량적영향.방법:선취부합입선표준적병례60례,수궤분성량조,치료조(금룡효낭연합TACE)30례,대조조(단순TACE)30례.매30천위1개주기,균완성지소2개주기.관찰량조림상증상、AFP변화、간공능분급개선、불량반응등,용간암환자특이성생명질량평개량표,진행생존질량평개.결과:①치료조CR 0례,PR 7례,SD 18례,PD 5례,공제솔(CR+ PR+SD)83.33%;대조조 CR 0례,PR 5례,SD 13례,PD 12례,공제솔(CR+ PR+SD)60.00%,치료조우우대조조(P<0.05).②치료조환자치료후검측AFP함량,개선솔23.33%、은정솔위60.00%、악화솔위16.67%,대조조환자치료후혈청AFP함량개선솔20.00%、은정솔위53.33%、악화솔위26.67%,량조간비교차이무통계학의의(P>0.05).③치료조간공능분급(Child-Pugh)개선솔、분급공제솔우우대조조(P<0.05).④치료조위장반응、백세포하강、혈홍단백、혈소판하강발생솔저우대조조,단차이무통계학의의(P>0.05).⑤생존질량적평개:재개선구체공능、심리공능、사회공능、총생존질량방면,치료조우우대조조(P<0.05).결론:금룡효낭배합간동맥개입화료가제고림상료효、개선간공능、감경간암TACE불량반응、제고환자생존질량,치득림상추엄응용.
Objective: This study aims to evaluate the influence of Jinlong capsule combined with Transarterial Chemo-embolization (TACE) on the quality of life of patients with primary liver cancer. Methods: A total of 60 cases of patients who met the inclusion criteria were randomly divided into two groups, namely, treatment group (Jinlong Capsule combined with TACE; 30 patients) and control group (treated with TACE only; 30 cases). The patients were administrated with TACE every 30 days as one cycle, and completed at least two cycles. Clinical symptoms, AFP, changes in liver function, adverse reactions, and quality of life evaluation were observed. Results: 1) In the treatment group, the CR had 0 case, PR had 7, SD had 18, and PD had 5 cases, with the control rate (CR+PR+SD) of 83.33%. In the control group, the CR had 0 case, PR had 5, SD had 13, and PD had 12 cases, with the control rate (CR+PR+SD) of 60.00%. The difference between the two groups was statistically significant (P<0.05). 2)The improvement, stable, and deterioration rates of the AFP levels detected in the treatment group were 23.33%, 60.00%, and 16.67%, respectively; whereas those in the control group were 20.00%, 53.33%, and 26.67%, respectively. The difference between the two groups was not statistically significant (P>0.05). 3) The liver function (Child-pugh) rate of improvement and grading control rate in the treatment group were higher than the control group; the differences were statistically significant (P<0.05). 4) The gastrointestinal reactions, leukopenia, hemoglobin, and platelet decline incidence in treatment group is lower than those of the control group; however, the difference was not statistically significant (P>0.05). 5) For the quality of life evaluation, improvement of physical function, psychological function, social function, and the total quality of life of the treatment group was higher than those of the control group;the difference was statistically significant (P<0.05). Conclusion: Jinlong capsule was combined with TACE in the treatment of patients with primary liver cancer. This combination can improve the clinical outcomes, liver function, reduce the TACE drug side effects, and improve the patient quality of life; thus is worthy of clinical application.